https://orcid.org/0000-0002-8072-7693
References
- Chapman S, Delgadillo D, III, Barber C, et al. Cutaneous squamous cell carcinoma complicating hidradenitis suppurativa: a review of the prevalence, pathogenesis, and treatment of this dreaded complication. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27(1):25–28.
- Jourabchi N, Fischer AH, Cimino-Mathews A, et al. Squamous cell carcinoma complicating a chronic lesion of hidradenitis suppurativa: a case report and review of the literature. Int Wound J. 2017;14(2):435–438.
- Segura Palacios JM, Garcia Montero P, Funez Liebana R, et al. Human papilloma virus and the risk of squamous cell carcinoma arising in hidradenitis suppurativa. Actas Dermosifiliogr. 2018;109(5):457–459.
- Jemec GB, Heidenheim M, Nielsen NH. A case-control study of hidradenitis suppurativa in an STD population. Acta Derm Venereol. 1996;76(6):482–483.
- Lavogiez C, Delaporte E, Darras-Vercambre S, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology. 2010;220(2):147–153.
- Nikkels A, Lebas E. Should we provide anti-human papillomavirus vaccination for patients with genital hidradenitis suppurativa? Br J Dermatol. 2019;180(1):233–233.
- CDC Advisory Committee on Immunization Practices (ACIP) Votes to Provisionally Recommend Shared Clinical Decision-Making for Vaccination of Adults Ages 27–45 with GARDASIL®9 & Harmonization of Catch-up Vaccination for Males and Females Through Age 26 Business Wire. 2019 [cited 2020].
- Castellsague X, Schneider A, Kaufmann AM, et al. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol. 2009;115(3):S15–S23.
- Van Damme P, Meijer C, Kieninger D, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34(35):4205–4212.
- Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–2159.
- Roy CF, Roy SF, Ghazawi FM, et al. Cutaneous squamous cell carcinoma arising in hidradenitis suppurativa: a case report. SAGE Open Med Case Rep. 2019;7:2050313X19847359.
- Giesey R, Delost GR, Honaker J, et al. Metastatic squamous cell carcinoma in a patient treated with adalimumab for hidradenitis suppurativa. JAAD Case Rep. 2017;3(6):489–491.